Sumatriptan dura

Quick links to important sections

Sumatriptan dura

Method of action: Analgesic, Antimigraine, Serotonergic

Treatment option: Headache, Cluster Headache, Migraine

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sumatriptan dura

Property Description
Active ingredient Sumatriptan Succinate
Form Oral tablet (Film-coated)
Pharmacological class Selective Serotonin (5-HT)1 Receptor Agonist
Common use Acute management of established neurovascular head pain
Origin Synthetic compound

Defining Sumatriptan dura: Chemical Identity and Pharmacological Class

Sumatriptan dura is a brand-specific pharmaceutical preparation containing the active compound Sumatriptan Succinate, which is classified as a Triptan. This category is formally known as a Selective Serotonin (5-HT)1 Receptor Agonist, identifying it as a synthetic molecule designed to specifically interact with neural pathways modulated by the neurotransmitter serotonin. Its pharmacological classification is characterized by its targeted action, distinguishing it from over-the-counter, non-selective analgesics.

Origin and General Purpose of Sumatriptan

The core purpose of Sumatriptan is its application as an acute, abortive treatment for established episodes of neurovascular head pain in adults. The drug's mechanism is designed to address the underlying factors contributing to the pain rather than providing non-specific relief. Its general use is typically observed in scenarios where a patient requires rapid intervention to interrupt the episode, making this targeted approach a cornerstone of modern acute management protocols.

Sumatriptan Forms: Identity of the Dura Tablet

The specific brand Sumatriptan dura is presented as an oral tablet and is consistently manufactured as a single active ingredient product. While the core compound Sumatriptan is also formulated for faster-acting methods, such as injection and nasal spray, the oral tablet ensures a convenient and non-invasive route of administration. The "dura" presentation confirms this identity as a film-coated tablet, delivering the standardized dose of the active pharmaceutical ingredient.

Regulatory References

  1. Sumatriptan - StatPearls - NCBI Bookshelf

What side effects are possible with Sumatriptan dura?

Official Classification of Possible Side Effects

The safety profile of Sumatriptan is organized by regulatory authorities into frequency-based categories and System-Organ-Classes (SOC). Adverse reactions officially documented as Common (may affect up to 1 in 10 people) typically involve sensations of tightness, pressure, or heaviness, which can occur in the chest, throat, or jaw, and are generally transient.

Other common effects listed in regulatory documents include dizziness, drowsiness, paresthesia (tingling), flushing, and transient increases in blood pressure.

Serious Adverse Reactions and Safety Constraints

The primary safety constraint is related to the drug’s vasospastic action. Regulatory documents explicitly list serious adverse reactions that are rare but clinically significant, including Myocardial Ischemia, Myocardial Infarction, and Cerebrovascular Events (such as stroke). Events are also reported under the Not Known frequency, including certain cardiac arrhythmias and anaphylactic reactions.

Official labeling mandates that use is contraindicated in patients with a history of Ischemic Heart Disease or uncontrolled hypertension. Furthermore, the drug is restricted for individuals with severe hepatic impairment.

Time-Related and Population Safety Notes

The safety profile notes that sensations of pressure and heaviness commonly appear soon after treatment and are usually short-lived. A separate regulatory caution addresses the risk of Medication Overuse Headache, which is associated with the frequent use of acute headache medications, including triptans, for ten or more days per month.

For specific populations, official guidelines advise that patients with multiple cardiovascular risk factors should receive a cardiovascular evaluation prior to starting treatment.

Overdose and Emergency Response

The regulatory documentation for Sumatriptan details the potential consequences of overconsumption, which are primarily related to the drug's potent vasoconstrictive effects. Officially documented overdose manifestations include severe vasospastic reactions, such as tightness or pain in the chest, throat, or jaw, as well as complications like peripheral vascular ischemia and severe transient increases in blood pressure.

The most serious outcomes that trigger urgent help-seeking are the life-threatening events explicitly noted in the prescribing information. These include major cardiac arrhythmias (such as ventricular tachycardia or ventricular fibrillation), myocardial infarction resulting from coronary artery vasospasm, and cerebrovascular events (e.g., stroke). The risk of Serotonin Syndrome is also documented when the drug is taken in combination with certain other medications.

In any suspected overconsumption scenario, regulatory guidance requires that immediate medical attention be sought. Specifically, individuals must contact a hospital emergency department or a poison control center without delay. Management relies on employing general supportive measures because the official labeling confirms that no specific antidote to Sumatriptan is known. A critical procedural step is the required monitoring for signs or symptoms of overdose for at least 12 hours to manage and observe the potential for delayed serious effects.

Therapeutic Uses of Sumatriptan dura

What Sumatriptan Dura Treats: Main Uses and Benefits

This medication is commonly used to provide symptomatic relief during an acute headache episode and is applied where short-term symptom management is appropriate for severe migraine and cluster headaches.

Symptomatic Relief for Severe Headache Attacks

This medication is relevant for easing groups of symptoms that may become intense or disruptive, including the throbbing pain and associated manifestations. It is applied across domains where additional symptomatic support is needed, primarily addressing symptoms that become more disruptive during flare-ups and is relevant when supportive symptom management is appropriate.

Management of Associated Distress and Functional Disruption

Beyond pain, the medication is also relevant for easing symptoms that interfere with daily functioning, such as nausea, vomiting, and heightened sensitivity to external stimuli like light and sound. Managing these symptoms contributes to easing the overall symptom load and may assist with maintaining functional stability when symptoms interfere with routine activities.

This use supports the patient during difficult episodes by easing distress and may help patients cope more steadily with symptom fluctuations.

“It is applied in scenarios where additional management of discomfort is required, helping to ease the overall symptom load.”


Quick Fact: Relief for Neurovascular Pain

This medication is relevant for symptoms of increased neurological activity, such as the severe, pulsating head pain, which differ from symptoms related to musculoskeletal tension.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

Sumatriptan dura (oral tablet) is formally indicated for use in the adult population (18 to 65 years of age). Eligibility is strictly defined by major exclusions focused on cardiovascular and cerebrovascular health.

Classification Population/Condition
Contraindicated (Must Not Use) Ischemic Coronary Artery Disease (e.g., angina, history of heart attack, Prinzmetal's angina), Uncontrolled Hypertension, History of Stroke or TIA, Severe Hepatic Impairment, Wolff-Parkinson-White Syndrome, Peripheral Vascular Disease, or use within 2 weeks of stopping an MAO-A inhibitor.
Not Recommended Pediatric patients (under 18 years of age) and older adults (over 65 years of age), as safety and efficacy are not fully established in these groups.
Conditional Use Patients with multiple cardiovascular risk factors require a prior cardiac evaluation. Use in mild to moderate hepatic impairment may be restricted to lower doses (e.g., maximum of 50 mg).

For Pregnancy, the medicine should be used only if the expected maternal benefit outweighs the potential risk. Lactating individuals are advised to avoid breastfeeding for 8 to 12 hours after taking the tablet to minimize infant exposure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Sumatriptan Succinate defines specific constraints regarding co-administration with several medication classes.

Formally Contraindicated Combinations

Co-administration is strictly prohibited with drugs that affect the metabolic pathway or pose an additive vasospastic risk.

  • Monoamine Oxidase-A (MAO-A) Inhibitors: Co-use is contraindicated, as inhibiting MAO-A results in an approximately seven-fold increase in the systemic exposure of oral Sumatriptan. Administration must be separated by at least two weeks after discontinuing MAO-A inhibitor therapy.
  • Ergotamine-Containing Drugs and Other 5-HT1 Receptor Agonists (Triptans): Co-administration is contraindicated due to the risk of additive vasospastic effects. A minimum interval of 24 hours must separate the administration of Sumatriptan from these agents.

Pharmacodynamic and Other Interactions

Interactions that affect the central nervous system's serotonin activity are also noted in official documents. Co-administration with Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) has been associated with reports of Serotonin Syndrome, reflecting an additive effect.

Separately, official regulatory data notes no evidence of a pharmacokinetic interaction between oral Sumatriptan and alcohol. Population-specific constraints exist, as Sumatriptan use is formally contraindicated in patients with severe hepatic impairment due to altered clearance.

Mechanism of Action

Targeted Agonism of Serotonin 5-HT1 Receptors

Sumatriptan functions as a highly selective agonist on two specific serotonin receptor subtypes: 5-HT1 B and 5-HT1 D. This targeted binding initiates inhibitory signaling cascades within the trigeminovascular system, modulating its dual components.


Regulation of Pathological Vascular Tone

Activation of the 5-HT1 B receptors, which are located on the smooth muscle of intracranial extracerebral arteries (e.g., dural arteries), causes these blood vessels to contract. This physiological change contributes to the regulation of vascular tone and limiting abnormal dilation in the meningeal circulation.


Modulation of Nociceptive Signaling and Neurogenic Inflammatory Mediators

Simultaneously, the drug acts on 5-HT1 D receptors situated on the peripheral terminals of the trigeminal nerves. By agonizing these pre-synaptic receptors, Sumatriptan inhibits the release of potent vasoactive neuropeptides like Calcitonin Gene-Related Peptide (CGRP), thereby suppressing neurogenic inflammation and reducing afferent nociceptive signal transmission.

Dosage and Administration Information

The use of Sumatriptan dura (oral tablet) is intended for the acute, intermittent treatment of established migraine attacks; it is not indicated for prophylactic use. The designated route of administration for this product is oral.


Official Dosing and Administration

Instruction Domain Standard Specification
Standard Single Dose Doses are available in 25 mg, 50 mg, or 100 mg strengths. The maximum single dose for adults is 100 mg.
Maximum Frequency The maximum total dose permitted within a 24-hour period is 200 mg. Doses must be separated by a minimum interval of 2 hours.
Administration The tablet must be swallowed whole with a liquid and must not be crushed, broken, or chewed. It may be taken with or without food.
Response Protocol If the initial dose provides no relief for a particular attack, a second dose is not to be taken for that same attack. If the symptoms return after initial relief, a second dose may be taken after the required minimum interval.

Use in Specific Populations

For patients with mild to moderate hepatic impairment, the maximum single dose is restricted to 50 mg. The use of the oral tablet is not generally recommended for children and adolescents under 18 years of age, nor in individuals over 65 years, due to limited data in these age groups.

Procedural Structure: The drug is to be administered on an as-needed basis at the onset of an episode, following a framework for single-dose selection, time separation between doses, and a limit on total daily intake. This ensures the procedural application of the drug remains consistent with the intended acute episodic use protocol.

Recent Clinical Evidence

Recent Clinical Evidence

Overview of Clinical Research

Research has been conducted to characterize the combination therapy, primarily focusing on its application in moderate-to-severe acute pain. Studies evaluated the potential application of the combination in moderate-to-severe pain, particularly in the post-operative setting.

Multiple large-scale studies have examined the difference in observed pain score changes between this dual approach and either component alone. The studies consistently show changes in pain scores, and these changes were compared to single-agent therapies.

Efficacy and Observed Changes

A body of evidence from Randomized Controlled Trials (RCTs) has focused on characterizing the observed pain profile. One key meta-analysis examined pain score changes observed in research following administration of the combination. The drug's activity was a key area of study.

Tolerability and Safety Profile

The tolerability and observed side effect profile of the combination therapy was evaluated across a range of patient populations. Research has also explored the tolerability and observed side effects of the combined therapy in patients with controlled, mild-to-moderate renal or hepatic impairment.

The drug's activity has been studied concerning its impact on adverse events. A retrospective review suggested that the incidence of some common opioid-related side effects, such as nausea and vomiting, was similar to single-agent opioids at equianalgesic doses, while others, like constipation, were reviewed across several studies.

Pharmacokinetic Studies

The two components are metabolized in the liver. Studies found that the elimination half-life of both components was largely predictable in patients with normal organ function. This finding was included in the evaluation of administration characteristics.

Limited research is available for patients with severe organ dysfunction. Therefore, the available data are generally insufficient to characterize the combination in people with severe liver disease.

Safety Monitoring

A serious adverse event, respiratory depression, was tracked during clinical studies. Other adverse events, such as dizziness and somnolence, were also tracked.

The consensus was focused on the findings related to the combination.

Frequently Asked Questions (FAQ)

Common questions about Sumatriptan dura (FAQ)


Q: Is Sumatriptan dura the same as other sumatriptan medications?

Sumatriptan dura is the brand name given to one preparation of the drug sumatriptan succinate. The active ingredient itself is widely available under various other brand names and as generic medicine. These forms contain the same core active ingredient, sumatriptan succinate.


Q: Can Sumatriptan dura help with tension headaches?

According to official product information, Sumatriptan dura is specifically indicated for the acute treatment of established migraine attacks. Treatment for other types of headaches, such as tension headaches, is not included in the official regulatory indications for this medicine.


Q: How quickly does Sumatriptan dura typically start to work?

Clinical study results often indicate that pain relief may begin within a specific timeframe, such as 30 to 60 minutes, after taking the oral dose. This is based on summaries of the drug’s performance found in regulatory documents.


Q: What is the expected duration of effect for Sumatriptan dura?

Official documents summarize clinical trial data that describe how long patients remained pain-free or had sustained relief. This data often tracks the percentage of individuals whose migraine symptoms did not return within a set period, such as 24 hours.


Q: Can I take Sumatriptan dura if I'm already taking daily medication for high blood pressure?

Regulatory guidelines clearly state that use is contraindicated (must not be used) in people with uncontrolled hypertension. Official information indicates that a prior cardiovascular evaluation may be required for individuals with multiple cardiovascular risk factors.


Q: Is Sumatriptan dura safe to use with standard painkillers like ibuprofen or acetaminophen?

While these specific non-selective pain relievers are not listed in official drug interaction sections, regulatory documents include a general caution regarding the frequent use of any acute headache treatment. This frequent use is associated with a safety concern known as Medication Overuse Headache.


Q: Why do doctors prescribe this specific form of sumatriptan?

Sumatriptan is manufactured in several ways, including injection and nasal spray. The oral tablet form is described in regulatory documents as a convenient route of administration that provides a standardized dose of the active ingredient.


Q: What is the difference between this and a CGRP inhibitor?

Sumatriptan is classified as a selective serotonin 5-HT1 receptor agonist, meaning it interacts with specific nerve receptors modulated by serotonin. CGRP inhibitors are a different, more recently developed class of medicine that act by blocking the CGRP molecule or its receptor, representing an alternate pharmacological approach.


Q: Can Sumatriptan dura affect my ability to drive?

Official safety documentation notes that the migraine attack itself can influence daily activities. Due to common effects like dizziness or drowsiness, official safety documents state that a person’s ability to safely operate machinery or drive may be affected.


Q: Where can I find official information about Sumatriptan dura?

You can find the full official documents for this drug, such as the Prescribing Information or the Summary of Product Characteristics, directly on the websites of government drug authorities. These authorities include the FDA, EMA, NIH, and MHRA (Gov.UK).


Q: Does Sumatriptan dura cause changes in mood or anxiety?

Official regulatory documents list a comprehensive range of undesirable effects. While mood or anxiety changes may not be among the most common reports, the full list does include other central nervous system effects, such as dizziness and drowsiness.


Q: Is Sumatriptan dura considered a controlled substance?

According to drug enforcement agencies and regulatory bodies in countries like the US, UK, and Canada, Sumatriptan is not classified as a controlled substance.


Q: Can Sumatriptan dura affect my sleep?

The drug's official list of common side effects includes central nervous system effects like drowsiness and dizziness. As these effects influence wakefulness, they may also influence an individual's normal sleep/wake cycle.


Q: Is Sumatriptan dura effective for migraines with aura?

The drug's indication, as stated in regulatory documents, is the acute treatment of established migraine attacks. Official labeling indicates the drug is for established migraine attacks and does not typically make a specific distinction about effectiveness based on the presence of an aura.


Q: Are there any signs that a side effect is serious and requires medical attention?

Official documents list certain symptoms, such as severe chest pain, sudden difficulty breathing, or signs of a stroke, as reasons to seek immediate medical attention. These are rare but serious adverse reactions listed in the safety documentation.


Q: Does Sumatriptan dura interact with herbal supplements like St. John's Wort?

Official regulatory warnings specifically mention the potential for interaction with supplements that influence serotonin levels. One such supplement often cited is St. John's Wort (Hypericum perforatum), as co-administration has been associated with a risk of contributing to Serotonin Syndrome.


Q: Why is it important to take Sumatriptan dura early in a migraine attack?

Sumatriptan is officially intended for use in the acute phase of a migraine attack. Studies summarized in regulatory documents indicate that the effectiveness of triptan medicines is generally higher when the drug is taken early during the headache phase.


Q: Does taking Sumatriptan dura cause dependence?

While Sumatriptan is not classified as a controlled substance, official documents include a warning about the potential for overuse. The risk of developing Medication Overuse Headache (MOH) is associated with using the medicine too frequently.


Q: What kind of studies confirm the drug's purpose?

The effectiveness and regulatory purpose of the drug are confirmed by scientific data. This evidence is primarily derived from large-scale studies, known as Randomized Controlled Trials (RCTs), conducted to evaluate the drug's performance against migraine.


Q: How is Sumatriptan dura different from over-the-counter migraine treatments?

Sumatriptan is classified as a selective serotonin 5-HT1 receptor agonist, meaning it has a targeted mechanism of action. This selective action on the blood vessels and nerves involved in migraine is fundamentally different from the non-selective mechanism of over-the-counter pain relievers.


Q: What is the scientific basis for who should not use Sumatriptan dura?

The drug’s mechanism of action involves the constriction of blood vessels (vasoconstriction). This effect is the scientific basis for the contraindications in individuals with certain pre-existing heart or circulatory conditions.


Q: Is the 'dura' form associated with a specific speed of action?

The oral tablet form has a standardized absorption rate described in regulatory pharmacokinetic data. Official documents note that other forms of sumatriptan, such as injections, are typically faster-acting, making the oral tablet a formulation with a slower, but non-invasive, delivery profile.


Q: Can caffeine affect how Sumatriptan dura works?

Specific interaction studies with pure caffeine are not typically detailed in official labeling. However, the regulatory documentation does caution that frequent use of medicines or products containing caffeine (as seen in some combination products) can contribute to the risk of Medication Overuse Headache.


Q: Does Sumatriptan dura commonly cause nausea?

The comprehensive list of side effects in regulatory documents includes effects that are categorized by frequency. While nausea may not be listed as a common effect (affecting 1 in 10 people or less), it is documented as an undesirable effect, often classified as uncommon or rare.


Q: What if I forget that I've taken Sumatriptan dura and take it again?

Official guidelines define a strict maximum total dose permitted within any 24-hour period and a minimum required time interval between doses. Exceeding these limits increases the risk of side effects related to the medicine’s mechanism of action.


Q: Can using Sumatriptan dura affect my vision?

The official documentation notes that certain sensory disturbances are listed under the less frequent or rare side effects. These can include visual disturbances or transient changes in vision.


How should Sumatriptan dura be stored and disposed of?

Sumatriptan tablets must be stored according to official regulatory specifications to maintain product stability and safety. The labeled storage conditions for the tablets generally require them to be kept at room temperature, away from excessive heat, moisture, and direct light. For some formulations, the label specifies a maximum storage temperature not exceeding 30 C or 25 C and explicitly prohibits freezing the medicine.

To ensure safety, the product must be kept out of the sight and reach of children. Unused or expired tablets should not be thrown away via wastewater or household waste. Regulatory documents mandate that disposal of unused product or waste material must be conducted in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sumatriptan dura found in:

A-Z Index: